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Background: Genome-wide significant associations of schizophrenia with eight SNPs in the CNNM2, MIR137,
PCGEM1, TRIM26, CSMD1, MMP16, NT5C2 and CCDC68 genes have been identified in a recent mega-analysis of
genome-wide association studies. To date, the role of these SNPs on gray matter (GM) volumes remains unclear.
Methods: After performing quality control for minor-allele frequency > 5% using a JPT HapMap sample and our
sample, a genotyping call rate > 95% and Hardy-Weinberg equilibrium testing (p > 0.01), five of eight SNPs were
eligible for analysis. We used a comprehensive voxel-based morphometry (VBM) technique to investigate the effects
of these five SNPs on GM volumes between major-allele homozygotes and minor-allele carriers in Japanese patients
with schizophrenia (n = 173) and healthy subjects (n = 449).
Results: The rs7914558 risk variant at CNNM2 was associated with voxel-based GM volumes in the bilateral inferior
frontal gyri (right T = 4.96, p = 0.0088, left T = 4.66, p = 0.031). These peak voxels, which were affected by the variant,
existed in the orbital region of the inferior frontal gyri. Individuals with the risk G/G genotype of rs7914558 had
smaller GM volumes in the bilateral inferior frontal gyri than carriers of the non-risk A-allele. Although several effects
of the genotype and the genotype-diagnosis interaction of other SNPs on GM volumes were observed in the
exploratory VBM analyses, these effects did not remain after the FWE-correction for multiple tests (p > 0.05).
Conclusions: Our findings suggest that the genetic variant in the CNNM2 gene could be implicated in the
pathogenesis of schizophrenia through the GM volumetric vulnerability of the orbital regions in the inferior frontal gyri.
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Schizophrenia is a common and complex psychiatric dis-
order with a lifetime risk of approximately 1%. This
disorder has a strong genetic component; indeed, the esti-
mated heritability is 81% [1]. Multiple genetic variants that
have a small effect have been implicated in the pathogen-
esis of schizophrenia [2]. A genome-wide association study
(GWAS) of single-nucleotide polymorphisms (SNPs) that* Correspondence: hashimor@psy.med.osaka-u.ac.jp
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reproduction in any medium, provided the oraccesses tens of thousands of DNA samples from patients
and controls can be a powerful tool for identifying common
risk factors for complex diseases, such as schizophrenia. To
date, GWASs on schizophrenia have identified several
genome-wide significant associated variants located in the
zinc finger protein 804A (ZNF804A), neurogranin (NRGN),
transcription factor 4 (TCF4) genes and a major histocom-
patibility complex (MHC) region [3,4]. Subsequently, the
influences of these SNPs in the genes on brain function and
structure have been reported [5]. We have found that the
genome-wide supported variant of the NRGN gene is asso-
ciated with the brain morphology of the anterior cingulate
cortex in patients with schizophrenia [6].. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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GWAS data from 17 separate studies (9,394 cases and
12,462 controls) and the replication data (8,442 cases and
21,397 controls) of European ancestry have found genome-
wide significant associations of schizophrenia with eight
SNPs [rs7914558 (cyclin M2; CNNM2), rs1625579 (micro-
RNA 137, MIR137), rs17662626 (PCGEM1, prostate-specific
transcript, PCGEM1), rs2021722 (tripartite motif containing
26, TRIM26), rs10503253 (CUB and Sushi multiple do-
mains 1, CSMD1), rs7004633 (matrix metallopeptidase
16, MMP16), rs11191580 (5′-nucleotidase, cytosolic II,
NT5C2) and rs12966547 (coiled-coil domain containing
68, CCDC68)] from the five new (1p21.3, 2q32.3, 8p23.2,
8q21.3 and 10q24.32-q24.33) and two previously reported
(6p21.32-p22.1 and 18q21.2) loci [7]. In studies exploring
brain activation during a sentence completion task, indi-
viduals without the risk allele of the MIR137 genotype had
significantly greater activation in the posterior right medial
frontal gyrus than at-risk individuals [8]. To our know-
ledge, however, no study has investigated the effects of
these SNPs on gray matter (GM) volumes.
Many attempts have been made to minimize the clinical
and genetic heterogeneity in studies of schizophrenia. One
strategy for gene discovery uses neurobiological quantita-
tive traits (QT) as intermediate phenotypes that reflect the
underlying genetic vulnerability better than diagnostic
categorization, such as schizophrenia [9,10]. This strategy
has the potential to reduce clinical and genetic heterogen-
eity [11]. Structural GM volumes indicate substantial
heritability rates ranging from moderate (40–70%) to high
(70–95%) in the frontal and temporal brain regions
[12,13]. Mata analyses of brain morphological studies in
individuals with first-episode schizophrenia and neuro-
leptic naive schizophrenia as well as chronic patients
with schizophrenia revealed reduction of GM volume
in frontal, striato-limbic and temporal regions were
present in the early stage of schizophrenia and were un-
related to the effects of neuroleptic treatment, chron-
icity and duration of illness [14-16]. Some studies have
shown that abnormalities in GM volumes are inter-
mediate phenotypes that bridge the gap between the
genotype and diagnostic categorization [11,17]. Charac-
terizing the functional effects of novel and poorly
understood genetic variants on the intermediate phe-
notypes provides important insights into the neural
mechanisms by which the variants increase the risk
for schizophrenia [18]. Our research group has had a
long-standing interest in the effects of genetic vari-
ants (i.e., COMT, DISC1, PACAP, BDNF, APOE, AKT1
and NRGN) on brain structure in psychiatric disor-
ders [6,19-24]. In this study, we examined the impact
of the genome-wide supported variants on the GM
volumes of patients with schizophrenia and healthy sub-
jects. Using a comprehensive voxel-based morphometry(VBM) technique, we tested the hypothesis that these risk
variants would be associated with GM volumes.
Material and methods
Subjects
VBM analyses were conducted on 173 patients with
schizophrenia (59.0% males, 102 males and 71 females,
mean age ± SD, range 36.0 ± 12.3 years) and 449 healthy
subjects (47.7% males, 214 males and 235 females, mean
age ± SD, range 35.4 ± 12.8 years). All subjects were bio-
logically unrelated within the second-degree of relationship
and were of Japanese descent [25,26]. The subjects were
excluded if they had neurological or medical conditions
that could potentially affect the central nervous system,
such as atypical headache, head trauma with loss of con-
sciousness, chronic lung disease, kidney disease, chronic
hepatic disease, thyroid disease, active cancer, cerebrovas-
cular disease, epilepsy, seizures, substance-related disorders
or mental retardation. Patients were recruited from the
Osaka University Hospital. Each patient with schizophrenia
had been diagnosed by at least two trained psychiatrists ac-
cording to the criteria from the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV)
based on the Structured Clinical Interview for DSM-IV
(SCID). Controls were recruited through local advertise-
ments at Osaka University. Psychiatrically, medically and
neurologically, the healthy subjects were evaluated using
the non-patient version of the SCID to exclude individuals
who had current or past contact with psychiatric services
or who had received psychiatric medication. Current symp-
toms of schizophrenia were evaluated using the positive
and negative syndrome scale (PANSS) [27]. Mean age and
handedness did not differ significantly between the study
group and the controls (p > 0.38), while the female ratio,
years of education, estimated premorbid intelligence quo-
tient (IQ) and total gray matter volumes were significantly
lower in the patients with schizophrenia compared to the
controls (p < 0.016) (Additional file 1: Table S1). All partici-
pants provided written informed consent after the study
procedures had been fully explained. This study was per-
formed in accordance with the World Medical Associa-
tion’s Declaration of Helsinki and was approved by the
Research Ethical Committee of Osaka University.
SNP selection and SNP genotyping
We selected eight SNPs, rs7914558, rs1625579, rs17662626,
rs2021722, rs10503253, rs7004633, rs11191580 and
rs12966547, from a previous mega analysis of GWASs
[7]. Of these eight SNPs, rs17662626 in the PCGEM1 gene
(2q32.3) was not polymorphic in the samples obtained
from the HapMap Japanese in Tokyo (JPT) project. Be-
cause the other seven SNPs were common genetic variants
in the HapMap JPT samples (minor allele frequency > 5%),
we focused on these SNPs. Venous blood was collected
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whole blood according to standard procedures. These
SNPs were genotyped using the TaqMan 5′-exonucle-
ase allelic discrimination assay (Assay ID: rs7914558:
C__31978821_10, rs1625579: C___8946584_20, rs2021722:
C__11690541_10, rs10503253: C___1503810_20, rs7004633:
C__29048976_10, rs11191580: C__31656012_10 and
rs12966547: C____152930_10, Applied Biosystems, Foster
City, CA, USA), as previously described [19,22]. Detailed in-
formation on the PCR conditions is available upon request.
The genotyping call rates were 98.2% (rs7914558), 97.9%
(rs1625579), 83.6% (rs2021722), 97.9% (rs10503253), 97.9%
(rs7004633), 99.8% (rs11191580) and 97.6% (rs12966547).
No deviation from the Hardy-Weinberg equilibrium (HWE)
in the examined SNPs was detected in the patients or in con-
trols (p > 0.01), with the exception of rs2021722. A significant
deviation from HWE in the rs2021722 was found in both
the patients (p= 1.02 × 10-17) and controls (p = 2.05 × 10-36)
with a relative excess of CC homozygotes, TT homozygotes
and undetermined subjects. According to the dbSNP data-
base (National Center for Biotechnology Information), the
SNP is shown as a tri-allelic variant with T/C/A. A number
of genome-wide significant variants within MHC (6p21.32-
p22.1), including rs2021722, have been identified [7]. How-
ever, the MHC region has been excluded from further ana-
lysis. Analyzing the region is difficult because of its high
linkage disequilibrium (LD) and ethnic heterogeneity. Minor
allele frequencies of rs1625579 were under 5% in our patients
(3.2%) and controls (2.5%). Therefore, in this study, we ex-
cluded these SNPs rs2021722 and rs1625579 from the VBM
analyses. Genotype and allele distributions for each SNP in-
cluded in the VBM analyses between the patients with
schizophrenia and the controls are shown in Table 1. All risk
alleles were defined based on the previous GWAS [7]:
rs7914558 (major G-allele), rs10503253 (minor A-allele),
rs7004633 (minor G-allele), rs11191580 (major T-allele) and
rs12966547 (minor G-allele). To increase the statistical
power and decrease type I errors, homozygotes and the het-
erozygotes for the minor allele groups were combined and
treated as minor-allele carriers. In this study, we contrastedTable 1 Genotype and allele distributions for each SNP betwe
SNP IDs Gene Chr
Risk Genotype fre
allele +/+ +/− −/−
+/− SCZ (n = 173)
rs10503253 CSMD1 8p23.2 A/C 0.06 0.46 0.49
rs7004633 MMP16 8q21.3 G/A 0.03 0.37 0.60
rs7914558 CNNM2 10q24.32 G/A 0.23 0.53 0.24
rs11191580 NT5C2 10q24.33 T/C 0.49 0.42 0.09
rs12966547 CCDC68 18q21 G/A 0.15 0.44 0.41
Abbreviations: Chr Chromosome; SCZ patients with schizophrenia; CON healthy cont
For alleles, the first allele is the risk allele. All risk alleles are represented based on tGM volumes between minor allele carriers and major allele
homozygotes.
Magnetic resonance imaging procedure
All magnetic resonance imaging (MRI) studies were
performed on a 1.5 T GE Signa EXCITE system. A three-
dimensional volumetric acquisition of a T1-weighted gradi-
ent echo sequence produced a gapless series of 124 sagittal
sections using a spoiled gradient recalled acquisition in the
steady state (SPGR) sequence (TE/TR, 4.2/12.6 ms; flip
angle, 15°; acquisition matrix, 256 × 256; 1NEX, FOV, 24 ×
24 cm; slice thickness, 1.4 mm). Subjects with MRI abnor-
malities, such as infarcts, hemorrhages or brain tumors,
were screened out prior to including this study as part of
routine clinical diagnosis and treatment. Therefore, there
were no gross abnormalities in any of the subjects. Each
image was visually examined to eliminate images with mo-
tion or metal artifacts, and the anterior commissure-
posterior commissure line was adjusted. The MRI images
were processed using the VBM8 toolbox in Statistical Para-
metric Mapping 8 (SPM8; http://www.fil.ion.ucl.ac.uk/spm/
software/spm8/) running on MATLAB R2013a (Math-
Works, Natick, MA, USA) according to the VBM8-Toolbox
Manual (http://dbm.neuro.uni-jena.de/vbm8/VBM8-Manual.
pdf). The T1 images were normalized and segmented into
GM, white matter (WM) and cerebrospinal fluid (CSF) using
the VBM8 toolbox with defaults for the extended options.
The modulated non-linear only (i.e., with no affine com-
ponent) option was selected to create volumetric GM par-
titions. Finally, the images were smoothed with an 8-mm
full-width, half-maximum isotropic Gaussian kernel.
Statistical analyses
In genetic association analysis, we performed power calcula-
tions using the Power Calculator for Two-Stage Association
Studies (http://www.sph.umich.edu/csg/abecasis/CaTS/) [28].
The power estimate was based on an allele frequency of 0.53
at rs7914558, a prevalence of 0.01, an alpha level of 0.05, and
assuming varying degrees of odds ratio using a multiplicative
model. In brain morphological analyses, we performed poweren the patients with schizophrenia and healthy subjects
quencies Risk allele Allelic OR
+/+ +/− −/− frequencies p value (95% CI)
CON (n = 449) SCZ CON (χ2)
0.09 0.46 0.45 0.29 0.32 0.22 (1.5) 1.19 (0.90-1.56)
0.06 0.36 0.57 0.21 0.25 0.24 (1.4) 1.20 (0.89-1.61)
0.29 0.49 0.22 0.49 0.53 0.23 (1.4) 1.16 (0.91-1.49)
0.50 0.42 0.07 0.70 0.72 0.55 (0.4) 1.09 (0.83-1.43)
0.17 0.44 0.39 0.37 0.39 0.54 (0.4) 1.09 (0.84-1.41)
rols; +, risk allele; -, non-risk allele; OR odds ratio.
he previous GWAS [7].
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power estimate was based on an alpha level of 0.05, a power
of 0.80 and assuming varying degrees of effect size using
t tests. Standardized effect sizes were calculated using
Cohen’s dmethod (http:www.uccs.edu/faculty/lbecker).
Statistical analyses of the demographic variables were
performed using PASW Statistics 18.0 software (SPSS
Japan Inc., Tokyo, Japan). Based on the assumption that
most of demographic variables, such as age and education
years, were not fitted to a normality distribution with the
Kolmogorov-Smirnov test (p < 0.05), differences in clinical
characteristics between patients and controls or between
genotypes were analyzed using the non-parametric Mann–
Whitney U-test for continuous variables, such as age and
years of education, and χ2 tests for categorical variables,
such as gender and handedness, as shown in Additional
file 1: Table S1-S3. The presence of HWE was examined
using the χ2 test for goodness-of-fit via SNPAlyze V5.1.1
Pro software (DYNACOM, Yokohama, Japan). The allelic
distributions of each SNP between patients and controls
were analyzed using χ2 tests with the SNPAlyze software.
The significance levels for HWE and other statistical tests
were set at two-tailed p-values, p < 0.01 and p < 0.05,
respectively.
We performed a comprehensive exploratory whole brain
search using the SPM8 statistical tools to examine the ef-
fects of the diagnosis, the genotype and their interaction of
each SNP on GM volume in patients with schizophrenia
and healthy subjects. As two-way ANOVA can simultan-
eously investigate these effects only in one model, these ef-
fects on GM volume were statistically assessed using a full
factorial model for a 2 × 2 ANOVA with diagnosis (cases
and controls) and genotype status (major-allele homozy-
gotes and minor-allele carriers) as independent variables in
SPM8. Gray matter volumes are correlated with age, and
gender and years of education differed significantly be-
tween the patient and the control groups (Additional file 1:
Table S1). Therefore, age, gender and years of education
were included as covariates of no interest into the analyses
to control for confounding variables. We contrasted GM
volumes between the diagnostic groups (smaller volume
region in patients with schizophrenia compared with
healthy subjects), the genotype groups (smaller or larger
volume region in minor-allele carriers relative to major-
allele homozygotes) or the genotype-diagnosis inter-
action. Non-sphericity estimation was used. We applied
a voxel-level height threshold of p < 0.001 (uncorrected for
multiple comparisons) and clusters of more than 100 con-
tiguous voxels were considered for the exploratory VBM
analyses. And then we applied family-wise error (FWE) cor-
rection for multiple testing to avoid type I errors at the
whole brain level. Eventually, the significance level was set
at p < 0.05 (FWE-corrected). To obtain a cluster as large as
possible, we extracted relative GM volumes from nominalclusters in bilateral inferiror frontal gyri at the lenient uncor-
rected threshold of p < 0.001 and cluster sizes > 100. The
extraction of these relative GM volumes were performed after
including confounding factors such as age, sex and education
years and modulated by total brain volumes in the VBM ana-
lyses. Anatomic localization was performed according to both
the MNI coordinates and Talairach coordinates, which were
obtained from M. Brett’s transformations (http://imaging.
mrc-cbu.cam.ac.uk/imaging/MniTalairach) and presented as
Talairach coordinates.
Results
Our study size of 173 cases and 449 controls had suffi-
cient power (>80%) to detect a genetic effect at odds
ratio of 1.43 or greater for rs7914558 when the allele
frequency was 0.53. Unfortunately, in our sample sizes,
there was no allelic association with schizophrenia for
any of the five SNPs [rs7914558 (CNNM2), rs10503253
(CSMD1), rs7004633 (MMP16), rs11191580 (NT5C2)
and rs12966547 (CCDC68)] (p > 0.22, Table 1).
We investigated the effects of diagnosis (cases and con-
trols), genotype (major-allele homozygotes and minor-
allele carriers) and their interaction of five SNPs on GM
volumes in a comprehensive exploratory VBM analysis.
The effects of diagnosis between patients with schizophre-
nia and healthy subjects were found in all analyses of the
present study (p < 0.05). Patients with schizophrenia
showed smaller GM volumes compared with healthy sub-
jects primarily in the frontal and temporal lobes, including
the bilateral inferior frontal gyri, which was consistent with
previous studies [14,30]. We found significant effects for
the risk-allele homozygotes of rs7914558 on decreased
GM volume in the bilateral inferior frontal gyri (right, T =
4.96, p = 0.0088; left, T = 4.66, p = 0.031), as shown in
Table 2 and the regions based on the hot color map in
Figure 1. To compare the effects of the genotype in both
the patients with schizophrenia and healthy subjects, we
extracted the means and SD for relative GM volumes from
nominal clusters in bilateral inferior frontal gyri and
the extracted GM volumes were shown in Figure 2 and
Additional file 1: Table S2. The risk G-allele homozygotes
of the CNNM2 polymorphism had smaller GM volumes in
the bilateral inferior frontal gyri compared to the non-risk
allele carriers. The inferior frontal gyrus can be subdivided
into three macroanatomical structures: the orbital (Brod-
mann area: BA47), opercular (BA44) and triangular (BA45)
parts. In the present study, the peak GM regions affected
by the CNNM2 genotype existed in the orbital parts of the
bilateral inferior frontal gyri. When the two genotype
groups (G-allele homozygotes and A-allele carriers) were
divided into three genotype groups (individuals with G/G
genotype, G/A genotype and A/A genotype) and we per-
formed an additional VBM analysis using a multiple regres-
sion model, the number of risk G-allele was significantly
Table 2 Effects of the CNNM2 genotype and genotype-diagnosis interaction on GM volumes
Brain regions R/L BA CS
p values (peak) Talairach coordinates
T FWE x y z
Non-risk minor allele carrier > Risk major allele homozygote
Inferior frontal Gyrus R 11/47 1306 4.96 0.0088 22 31 −20
Inferior frontal Gyrus L 47 437 4.66 0.031 −22 18 −22
Middle frontal Gyrus L 11 667 4.33 0.11 −24 38 −18
Posterior cingulate L 29 248 3.73 0.61 −7 −48 11
Non-risk minor allele carrier < Risk major allele homozygote
no suprathreshold clusters
Genotype-diagnosis interaction
Superior temporal Gyrus L 22 598 4.23 0.16 −46 −20 1
Abbreviations: R right; L left; BA Brodmann area; CS Cluster size; FWE family-wise error.
All regions shown have nominal association at a voxel-level height threshold of uncorrected p < 0.001 and a minimum clusters extent of 100 voxels. Significant
results (FWE-corrected p < 0.05) are shown in bold face.
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gyrus (T = 4.67, p = 0.029) but not the left inferior frontal
gyrus (T = 3.64, p = 0.70) in total subjects.
As shown in Additional file 1: Table S1, patients with
schizophrenia participated in this study were chronic and
the symptoms were moderately stable. There was no dif-
ference in demographic information, such as duration of
illness or PANSS scores, between risk G-allele homozy-
gotes and non-risk A-allele carriers of rs7914558 (p > 0.20,
Additional file 1: Table S3). However, to find whether there
was potential clinical impact on our outcomes, we add-
itionally investigated the genotype effect on GM volumeFigure 1 Effects of the rs7914558 polymorphism at the CNNM2 gene
rs7914558 at CNNM2 on decreased GM regions (red areas shown on the ho
regions (blue area shown on the winter color map). Each color map showsincluding chlorpromazine equivalent of total antipsychotics
(mg/day), duration of illness or PANSS scores as covariant
for VBM analyses only in patients. The genotype effect on
these regions did not change even after controlling for
these factors, suggesting that there was no potential clinical
impact on our outcomes.
In the exploratory VBM analyses, we also found nominal
effects of the risk-allele homozygotes of rs7914558 on de-
creased GM volume in the left middle frontal gyrus and
the left posterior cingulate and a nominal genotype-
diagnosis interaction with the GM volume in the left su-
perior temporal gyrus (uncorrected p < 0.001, Table 2).on GM volumes. There were effects of the risk-allele carriers of
t color map). There was no effect of the genotype on increased GM
the t values corresponding to the color in the figure.
Figure 2 The impacts of the CNNM2 genotype on GM volume of the bilateral inferior frontal gyri. (A) Anatomical localizations are
displayed on coronal, sagittal, and axial sections of a normal MRI spatially normalized into the Montreal Neurological Institute template (p <0.05).
The most significant cluster of the genotype effect was in the right inferior frontal gyrus. The region is shown as a cross-hairline. The color bars
show the t values corresponding to the color in the figure. (B, C) Each column shows the relative GM volumes extracted from a nominal cluster
at uncorrected p < 0.001 and cluster size > 100 in the right inferior frontal gyrus (peak Talairach coordinates; 22, 31, -20) (B) and in the left inferior
frontal gyrus (peak Talairach coordinates; -22, 18, -22) (C). Error bars represent the standard error.
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and genotype-diagnosis interactions of other SNPs on GM
volumes in the exploratory analyses (uncorrected p < 0.001,
Additional file 1: Table S4 and Figure S1-S4). However,
these effects of genotypes and genotype-diagnosis interac-
tions on GM regions did not survive after the FWE-correc-
tion for multiple tests at the whole brain level (p > 0.05).
Discussion
To date, it remains unclear whether the genome-wide
significant risk variants for schizophrenia in a mega-
analysis of GWASs influenced GM volumes. This study
is the first to identify the GM morphology associated
with genome-wide risk variants using a comprehensive
VBM technique. Of the five genetic variants investigated
in this study, we found influences of the CNNM2 geno-
type on the bilateral inferior frontal gyri at the whole
brain level. GM volumes in the bilateral inferior frontal
gyri, particularly the orbital region, in the risk G-allele
homozygotes of CNNM2 polymorphism were smaller
than those observed in the non-risk allele carriers.
In genetic association analysis, our sample size had suffi-
cient power (>80%) to detect a genetic effect with odds ra-
tio of 1.43 or greater for rs7914558. However, previous
large GWAS has reported the genetic effect with low odds
ratio of 1.10 for the SNP [7]. To detect such a small gen-
etic effect, our sample size had insufficient power (12%),and a large sample size of at least 3400 patients and 3400
controls is needed. On the other hand, in brain morpho-
logical analyses, our sample size had sufficient power
(>80%) to detect a genotype effect on GM volumes at
medium effect size (Cohen’s d) of 0.25 or greater. The ob-
served effect sizes on the inferior frontal gyri were
medium to large (0.29-1.00). These findings suggest that
the genome-wide supported variant of schizophrenia had
larger effect on GM volumes of the inferior frontal gyri
than diagnostic status, and support that GM volumes ab-
normalities were prominent intermediate phenotypes
bridging the gap between a susceptibility genetic variant
and diagnostic categorization.
Rs7914558 is located in intron1 of the CNNM2 gene
(also known as ACDP2) on chromosome 10q24.32. The
CNNM2 gene spans 160.3 kb of genomic DNA and con-
tains eight exons. This gene belongs to a member of the
ancient conserved domain-containing protein family be-
cause the protein shares a domain conserved in a large
number of species ranging from bacteria to human [31].
Members of this protein family contain a sequence motif
that is present in the cyclin box, a cyclic nucleotide-
monophosphate (cNMP)-binding domain. The CNNM2
gene has a ubiquitous expression pattern in humans [31].
In particular, the level of CNNM2 expression in the
brain is moderate to high (http://www.ebi.ac.uk/gxa/
experiment/E-MTAB-37/ENSG00000148842).
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brains of patients with schizophrenia is lower or higher
than that in healthy subjects is unknown. The encoded
protein CNNM2 plays an important role in magnesium
homeostasis by modulating Mg2+ concentration. The
CNNM2 mRNA is upregulated when there is a defi-
ciency of magnesium in the brain [32]. CNNM2 medi-
ated Mg2 + −sensitive Na + currents were blocked by
increased extracellular Mg2+ concentrations [33]. We
assessed the effect of the rs7914558 genotype on
CNNM2 expression using bioinformatics data (http://
www.sanger.ac.uk/resources/software/genevar/[34]) to
examine whether the rs7914558 genotype might be an
expression quantitative trait loci (eQTL). In silico ana-
lysis showed that the CNNM2 gene expression of the
high-risk G genotype of rs7914558 was significantly
lower than that of the non-risk genotype in the com-
bined lymphoblast-derived HapMap CEU and YRI sam-
ples (r = −.23, t = −2.59, p = 0.011). The low expression
of this gene resulted increased Mg2+ levels. Increased
extracellular Mg2+ concentrations caused a decrease in
the activity of the glutamate N-methyl-D-aspartate
(NMDA) receptor [35]. These findings suggest that the
CNNM2 gene may play an important role in the hypo-
function of the NMDA receptor, which is implicated in
the pathophysiology of schizophrenia.
The inferior frontal gyrus has a multifunctional role in
human behavior, interpersonal interactions and communi-
cation [36]. The inferior frontal gyrus consists primarily of
the heteromodal association neocortex, which is a major
site of involvement in schizophrenia [37]. Several studies
have reported that the relative GM in patients with schizo-
phrenia was significantly reduced in the bilateral inferior
frontal areas [38-40]. The inferior frontal gyrus can be
subdivided into three macroanatomical parts: orbital,
opercular and triangular. The orbital region is one of the
major regions of the social brain that connects to the orbi-
tofrontal cortex [41], while the opercular and triangular
regions form Broca’s area, which is an important region
for speech-language production [42]. We found that the
CNNM2 genotype affects brain volumes in the orbital re-
gions of the inferior frontal gyri. Functionally, the orbital
region is thought to be involved in the processing of em-
pathy [36] and sentence comprehension [43,44] in the left
hemisphere and decision-making cognition [41] and fine
movement control [36] in the right hemisphere. Social
functions are widely impaired in patients with schizophre-
nia [45-49]. It is still unclear whether and to what extent
the effects of CNNM2 polymorphism on GM structure
observed here might be associated with an increased risk
for schizophrenia. We suggest that the CNNM2 variant
may play a role in the social cognition and social function-
ing impairments noted in patients with schizophrenia
through GM volumetric vulnerability of the orbital regionsof the inferior frontal gyri. Further research is needed to in-
vestigate how a possible relationship between the CNNM2
gene and hypofunction of the NMDA receptor would result
in decreased GM volumes of the inferior frontal gyri.
There was no significant effect of the other four variants
on any GM volumes. There are several possible reasons
for the absence of an association. A false negative associ-
ation cannot be excluded in our study because we applied
a strict FWE correction for multiple comparisons at the
whole brain level (p < 0.05). In the Additional file 1: Figure
S1-S4, the regions shown at the more lenient uncorrected
threshold of p < 0.001 may be helpful in further studies.
Interestingly, many of the effects of these genome-wide
significant variants at the lenient level involved decreased
GM volumes, including the medial, middle and inferior
fontal gyri. Reduced GM volumes in these regions have
been repeatedly demonstrated in imaging studies of
schizophrenia [14,30]. Another interpretation is that the
effect of these variants was not sufficiently sensitive to the
morphological vulnerability of the GM volumes. The effect
of these variants may be preferable in identifying genotype-
related vulnerability on other intermediate phenotypes,
such as cognitive functions and personality traits. There-
fore, further research is needed to confirm whether the ef-
fects of these variants could be related to the susceptibility
of cognitive functioning.
There were several limitations to this study. Because a
number of statistical analyses, including the effects of diag-
nosis, genotypes and their interaction on GM volumes,
were performed, a correction for multiple testing should
be considered. However, a consensus on how to correct
such multiple testing on study combining brain imaging
and genetics has not been reached in this research field.
To control type I errors, we applied the strict FWE correc-
tion for all VBM analyses, while we did not perform any
correction on the genetic modality. The existence of a false
positive association cannot be excluded as an explanation
for our results, although we were quite careful to match
ethnicity and correct for multiple testing. Further investi-
gations of other samples with much larger sample sizes
and/or with different ethnicities and/or in relatives of
those with schizophrenia are needed to confirm our
findings. It is unclear whether our results are directly/
indirectly linked to the CNNM2 polymorphism rs7914558,
to other polymorphisms in high LD with this variant or to
interactions between this variant and other variants. To
determine whether rs7914558 is the most strongly asso-
ciated variant for schizophrenia and brain structure in
this gene, an extensive search for other functional vari-
ants at this locus is needed. Additionally, as with other
risk variants for schizophrenia, clarifying the biological
role of this SNP through in vitro and in vivo studies is
important to improve the understanding of the patho-
physiology of schizophrenia.
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We found that a genome-wide supported variant of
CNNM2 could be associated with GM morphological vul-
nerability of the bilateral inferior frontal gyri. These results
suggest that there may be possible deleterious effects of the
risk G-allele at CNNM2 in the inferior frontal gyri, which
may, at least partially, represent the mechanism by which
CNNM2 increases the risk for schizophrenia. Further re-
search will be needed to clarify the function of the risk
CNNM2 variant on the pathophysiology of schizophrenia.
Additional file
Additional file 1: Table S1. Demographic information for patients with
schizophrenia and healthy subjects. Table S2: Effects of the rs7914558
genotype on extracted relative GM volumes of the bilateral inferior frontal gyri.
Table S3: Demographic information for risk G-allele homozygotes and non-
risk A-allele carriers of rs7914558. Table S4: Impacts of each genetic variant on
GM volumes in the exploratory VBM analyses. Figure S1: Effects of the
rs10503253 polymorphism (CSMD1) on GM volumes. Figure S2: Effects of the
rs7004633 polymorphism (MMP16) on GM volumes. Figure S3: Effects of the
rs11191580 polymorphism (NT5C2) on GM volumes. Figure S4: Effects of the
rs12966547 polymorphism (CCDC68) on GM volumes.
Abbreviations
GM: Gray matter; VBM: Voxel-based morphometry; GWAS: Genome-wide
association study; SNP: Single-nucleotide polymorphism; CNNM2: Cyclin M2;
QT: Quantitative traits; DSM-IV: Diagnostic and statistical manual of mental
disorders fourth edition; SCID: Structured clinical interview for DSM-IV;
HWE: Hardy-Weinberg equilibrium; LD: Linkage disequilibrium; MRI: Magnetic
resonance imaging; FWE: Family-wise error.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RH supervised the entire project, collected the data, wrote the manuscript, was
critically involved in the design, analysis and interpretation of the data and was
responsible for performing the literature review. KO was critically involved in the
collection and analysis of the data, and contributed to the editing of the final
manuscript and contributed intellectually to the interpretation of the data. HY
and SU took part in genotyping. HY, YY, MF, MF, YW, MI, HK and MT contribute
with sample collection and gave comments to the manuscript. All authors
contributed to and have approved the final manuscript.
Acknowledgments
We would like to thank all of the individuals who participated in this study.
This work was supported by research grants from the Japanese Ministry of
Health, Labor and Welfare (H22-seishin-ippan-001); KAKENHI, 22390225-Grant-
in-Aid for Scientific Research (B), 23659565-Grant-in-Aid for Challenging
Exploratory Research and Grant-in-Aid for Scientific Research on Innovative
Areas (Comprehensive Brain Science Network) from the Japanese Ministry of
Education, Culture, Sports, Science and Technology (MEXT); CREST of JST;
and the Japan Foundation for Neuroscience and Mental Health.
Author details
1Department of Psychiatry, Osaka University Graduate School of Medicine,
Osaka, Japan. 2National Hospital Organization, Yamato Mental-Medical
Center, Nara, Japan. 3Core Research for Evolutionary Science and Technology
of the Japan Science and Technology Agency, Saitama, Japan. 4Molecular
Research Center for Children’s Mental Development, United Graduate School
of Child Development, Osaka University, Osaka, Japan. 5Department of
Molecular Neuropsychiatry, Osaka University Graduate School of Medicine,
Osaka, Japan. 6Biofunctional Imaging, Immunology Frontier Research Center,
Osaka University, Osaka, Japan. 7Department of Radiology, Osaka University
Graduate School of Medicine, Osaka, Japan.Received: 23 July 2013 Accepted: 21 October 2013
Published: 25 October 2013References
1. Sullivan PF, Kendler KS, Neale MC: Schizophrenia as a complex trait:
evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003,
60:1187–1192.
2. Sun J, Kuo PH, Riley BP, Kendler KS, Zhao Z: Candidate genes for
schizophrenia: a survey of association studies and gene ranking. Am J
Med Genet B Neuropsychiatr Genet 2008, 147B:1173–1181.
3. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D,
Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O,
Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J,
Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A, Nordentoft
M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J, Breuer R, Moller
HJ, Giegling I, et al: Common variants conferring risk of schizophrenia.
Nature 2009, 460:744–747.
4. O’Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V,
Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini
JL, Spencer CC, Howie B, Leung HT, Hartmann AM, Moller HJ, Morris DW,
Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M,
Zammit S, Schumacher J, Quinn EM, Schulze TG, et al: Identification of loci
associated with schizophrenia by genome-wide association and follow-
up. Nat Genet 2008, 40:1053–1055.
5. Rose EJ, Donohoe G: Brain vs behavior: an effect size comparison of
neuroimaging and cognitive studies of genetic risk for schizophrenia.
Schizophr Bull 2013, 39:518–526.
6. Ohi K, Hashimoto R, Yasuda Y, Nemoto K, Ohnishi T, Fukumoto M,
Yamamori H, Umeda-Yano S, Okada T, Iwase M, Kazui H, Takeda M: Impact
of the genome wide supported NRGN gene on anterior cingulate
morphology in schizophrenia. PLoS One 2012, 7:e29780.
7. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY,
Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin
A, Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK,
Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D,
Ruderfer DM, Fanous A, Stefansson H, Steinberg S, et al: Genome-wide
association study identifies five new schizophrenia loci. Nat Genet 2011,
43:969–976.
8. Whalley HC, Papmeyer M, Romaniuk L, Sprooten E, Johnstone EC, Hall J,
Lawrie SM, Evans KL, Blumberg HP, Sussmann JE, McIntosh AM: Impact of a
microRNA MIR137 susceptibility variant on brain function in people at
high genetic risk of schizophrenia or bipolar disorder.
Neuropsychopharmacology 2012, 37:2720–2729.
9. Meyer-Lindenberg A, Weinberger DR: Intermediate phenotypes and
genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006,
7:818–827.
10. Tan HY, Callicott JH, Weinberger DR: Intermediate phenotypes in
schizophrenia genetics redux: is it a no brainer? Mol Psychiatry 2008,
13:233–238.
11. Potkin SG, Turner JA, Guffanti G, Lakatos A, Torri F, Keator DB, Macciardi F:
Genome-wide strategies for discovering genetic influences on cognition
and cognitive disorders: methodological considerations. Cogn
Neuropsychiatry 2009, 14:391–418.
12. Kaymaz N, van Os J: Heritability of structural brain traits an
endophenotype approach to deconstruct schizophrenia. Int Rev Neurobiol
2009, 89:85–130.
13. Rijsdijsk FV, Viding E, De Brito S, Forgiarini M, Mechelli A, Jones AP, McCrory E:
Heritable variations in gray matter concentration as a potential
endophenotype for psychopathic traits. Arch Gen Psychiatry 2010, 67:406–413.
14. Chan RC, Di X, McAlonan GM, Gong QY: Brain anatomical abnormalities in
high-risk individuals, first-episode, and chronic schizophrenia: an
activation likelihood estimation meta-analysis of illness progression.
Schizophr Bull 2011, 37:177–188.
15. Leung M, Cheung C, Yu K, Yip B, Sham P, Li Q, Chua S, McAlonan G: Gray
matter in first-episode schizophrenia before and after antipsychotic drug
treatment. Anatomical likelihood estimation meta-analyses with sample
size weighting. Schizophr Bull 2011, 37:199–211.
16. Ren W, Lui S, Deng W, Li F, Li M, Huang X, Wang Y, Li T, Sweeney JA, Gong
Q: Anatomical and functional brain abnormalities in drug-naive first-
episode schizophrenia. Am J Psychiatry. in press.
Ohi et al. Behavioral and Brain Functions 2013, 9:40 Page 9 of 9
http://www.behavioralandbrainfunctions.com/content/9/1/4017. Goldman AL, Pezawas L, Mattay VS, Fischl B, Verchinski BA, Chen Q,
Weinberger DR, Meyer-Lindenberg A: Widespread reductions of cortical
thickness in schizophrenia and spectrum disorders and evidence of
heritability. Arch Gen Psychiatry 2009, 66:467–477.
18. Meyer-Lindenberg A: Imaging genetics of schizophrenia. Dialogues Clin
Neurosci 2010, 12:449–456.
19. Hashimoto R, Hashimoto H, Shintani N, Chiba S, Hattori S, Okada T,
Nakajima M, Tanaka K, Kawagishi N, Nemoto K, Mori T, Ohnishi T, Noguchi
H, Hori H, Suzuki T, Iwata N, Ozaki N, Nakabayashi T, Saitoh O, Kosuga A,
Tatsumi M, Kamijima K, Weinberger DR, Kunugi H, Baba A: Pituitary
adenylate cyclase-activating polypeptide is associated with
schizophrenia. Mol Psychiatry 2007, 12:1026–1032.
20. Hashimoto R, Hirata Y, Asada T, Yamashita F, Nemoto K, Mori T, Moriguchi Y,
Kunugi H, Arima K, Ohnishi T: Effect of the brain-derived neurotrophic
factor and the apolipoprotein E polymorphisms on disease progression
in preclinical Alzheimer’s disease. Genes Brain Behav 2009, 8:43–52.
21. Hashimoto R, Moriguchi Y, Yamashita F, Mori T, Nemoto K, Okada T, Hori H,
Noguchi H, Kunugi H, Ohnishi T: Dose-dependent effect of the Val66Met
polymorphism of the brain-derived neurotrophic factor gene on
memory-related hippocampal activity. Neurosci Res 2008, 61:360–367.
22. Hashimoto R, Numakawa T, Ohnishi T, Kumamaru E, Yagasaki Y, Ishimoto T,
Mori T, Nemoto K, Adachi N, Izumi A, Chiba S, Noguchi H, Suzuki T, Iwata N,
Ozaki N, Taguchi T, Kamiya A, Kosuga A, Tatsumi M, Kamijima K, Weinberger
DR, Sawa A, Kunugi H: Impact of the DISC1 Ser704Cys polymorphism on
risk for major depression, brain morphology and ERK signaling. Hum Mol
Genet 2006, 15:3024–3033.
23. Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Nemoto K, Ohnishi T,
Yamamori H, Takahashi H, Iike N, Kamino K, Yoshida T, Azechi M, Ikezawa K,
Tanimukai H, Tagami S, Morihara T, Okochi M, Tanaka T, Kudo T, Iwase M,
Kazui H, Takeda M: The AKT1 gene is associated with attention and brain
morphology in schizophrenia. World J Biol Psychiatry 2013, 14:100–113.
24. Ohnishi T, Hashimoto R, Mori T, Nemoto K, Moriguchi Y, Iida H, Noguchi H,
Nakabayashi T, Hori H, Ohmori M, Tsukue R, Anami K, Hirabayashi N, Harada
S, Arima K, Saitoh O, Kunugi H: The association between the Val158Met
polymorphism of the catechol-O-methyl transferase gene and
morphological abnormalities of the brain in chronic schizophrenia.
Brain 2006, 129:399–410.
25. Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Iwase M, Iike N, Azechi M,
Ikezawa K, Takaya M, Takahashi H, Yamamori H, Okochi T, Tanimukai H,
Tagami S, Morihara T, Okochi M, Tanaka T, Kudo T, Kazui H, Iwata N, Takeda
M: The impact of a genome-wide supported psychosis variant in the
ZNF804A gene on memory function in schizophrenia. Am J Med Genet B
Neuropsychiatr Genet 2010, 153B:1459–1464.
26. Ohi K, Hashimoto R, Yasuda Y, Kiribayashi M, Iike N, Yoshida T, Azechi M,
Ikezawa K, Takahashi H, Morihara T, Ishii R, Tagami S, Iwase M, Okochi M,
Kamino K, Kazui H, Tanaka T, Kudo T, Takeda M: TATA box-binding protein
gene is associated with risk for schizophrenia, age at onset and
prefrontal function. Genes Brain Behav 2009, 8:473–480.
27. Lindenmayer JP, Bernstein-Hyman R, Grochowski S: A new five factor
model of schizophrenia. Psychiatr Q 1994, 65:299–322.
28. Skol AD, Scott LJ, Abecasis GR, Boehnke M: Joint analysis is more efficient
than replication-based analysis for two-stage genome-wide association
studies. Nat Genet 2006, 38:209–213.
29. Faul F, Erdfelder E, Lang AG, Buchner A: G*Power 3: a flexible statistical
power analysis program for the social, behavioral, and biomedical
sciences. Behav Res Methods 2007, 39:175–191.
30. Ellison-Wright I, Bullmore E: Anatomy of bipolar disorder and
schizophrenia: a meta-analysis. Schizophr Res 2010, 117:1–12.
31. Wang CY, Shi JD, Yang P, Kumar PG, Li QZ, Run QG, Su YC, Scott HS, Kao KJ,
She JX: Molecular cloning and characterization of a novel gene family of
four ancient conserved domain proteins (ACDP). Gene 2003, 306:37–44.
32. Goytain A, Quamme GA: Functional characterization of ACDP2 (ancient
conserved domain protein), a divalent metal transporter.
Physiol Genomics 2005, 22:382–389.
33. Stuiver M, Lainez S, Will C, Terryn S, Gunzel D, Debaix H, Sommer K, Kopplin K,
Thumfart J, Kampik NB, Querfeld U, Willnow TE, Nemec V, Wagner CA,
Hoenderop JG, Devuyst O, Knoers NV, Bindels RJ, Meij IC, Muller D: CNNM2,
encoding a basolateral protein required for renal Mg2+ handling, is
mutated in dominant hypomagnesemia. Am J Hum Genet 2011, 88:333–343.
34. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE,
Dunning M, Flicek P, Koller D, Montgomery S, Tavare S, Deloukas P,Dermitzakis ET: Population genomics of human gene expression.
Nat Genet 2007, 39:1217–1224.
35. Kochlamazashvili G, Bukalo O, Senkov O, Salmen B, Gerardy-Schahn R, Engel
AK, Schachner M, Dityatev A: Restoration of synaptic plasticity and
learning in young and aged NCAM-deficient mice by enhancing
neurotransmission mediated by GluN2A-containing NMDA receptors.
J Neurosci 2012, 32:2263–2275.
36. Liakakis G, Nickel J, Seitz RJ: Diversity of the inferior frontal gyrus–a meta-
analysis of neuroimaging studies. Behav Brain Res 2011, 225:341–347.
37. Ross CA, Pearlson GD: Schizophrenia, the heteromodal association
neocortex and development: potential for a neurogenetic approach.
Trends Neurosci 1996, 19:171–176.
38. Buchanan RW, Vladar K, Barta PE, Pearlson GD: Structural evaluation of the
prefrontal cortex in schizophrenia. Am J Psychiatry 1998, 155:1049–1055.
39. Yamasue H, Iwanami A, Hirayasu Y, Yamada H, Abe O, Kuroki N, Fukuda R,
Tsujii K, Aoki S, Ohtomo K, Kato N, Kasai K: Localized volume reduction in
prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an
MRI parcellation study. Psychiatry Res 2004, 131:195–207.
40. Suzuki M, Nohara S, Hagino H, Kurokawa K, Yotsutsuji T, Kawasaki Y,
Takahashi T, Matsui M, Watanabe N, Seto H, Kurachi M: Regional changes
in brain gray and white matter in patients with schizophrenia
demonstrated with voxel-based analysis of MRI. Schizophr Res 2002,
55:41–54.
41. Rogers RD, Owen AM, Middleton HC, Williams EJ, Pickard JD, Sahakian BJ,
Robbins TW: Choosing between small, likely rewards and large, unlikely
rewards activates inferior and orbital prefrontal cortex. J Neurosci 1999,
19:9029–9038.
42. Amunts K, Schleicher A, Burgel U, Mohlberg H, Uylings HB, Zilles K: Broca’s
region revisited: cytoarchitecture and intersubject variability. J Comp
Neurol 1999, 412:319–341.
43. Sakai KL, Nauchi A, Tatsuno Y, Hirano K, Muraishi Y, Kimura M, Bostwick M,
Yusa N: Distinct roles of left inferior frontal regions that explain
individual differences in second language acquisition. Hum Brain Mapp
2009, 30:2440–2452.
44. Sakai KL: Language acquisition and brain development. Science 2005,
310:815–819.
45. Bragado-Jimenez MD, Taylor PJ: Empathy, schizophrenia and violence: a
systematic review. Schizophr Res 2012, 141:83–90.
46. Sevy S, Burdick KE, Visweswaraiah H, Abdelmessih S, Lukin M, Yechiam E,
Bechara A: Iowa gambling task in schizophrenia: a review and new data
in patients with schizophrenia and co-occurring cannabis use disorders.
Schizophr Res 2007, 92:74–84.
47. Billeke P, Aboitiz F: Social cognition in schizophrenia: from social stimuli
processing to social engagement. Front Psychiatry 2013, 4:4.
48. Kuperberg GR, Kreher DA, Ditman T: What can event-related potentials tell
us about language, and perhaps even thought, in schizophrenia? Int J
Psychophysiol 2010, 75:66–76.
49. Vrtunski PB, Simpson DM, Weiss KM, Davis GC: Abnormalities of fine motor
control in schizophrenia. Psychiatry Res 1986, 18:275–284.
doi:10.1186/1744-9081-9-40
Cite this article as: Ohi et al.: The impact of the genome-wide
supported variant in the cyclin M2 gene on gray matter morphology in
schizophrenia. Behavioral and Brain Functions 2013 9:40.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
